Biocon Limited

NSE BIOCON.NS

Biocon Limited Goodwill for the year ending March 31, 2024: USD 1.96 B

Biocon Limited Goodwill is USD 1.96 B for the year ending March 31, 2024, a -0.02% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.
  • Biocon Limited Goodwill for the year ending March 31, 2023 was USD 1.96 B, a 56,367.05% change year over year.
  • Biocon Limited Goodwill for the year ending March 31, 2022 was USD 3.48 M, a -3.57% change year over year.
  • Biocon Limited Goodwill for the year ending March 31, 2021 was USD 3.61 M, a 2.92% change year over year.
  • Biocon Limited Goodwill for the year ending March 31, 2020 was USD 3.50 M, a -7.78% change year over year.
Key data
Date Goodwill Total Assets Current Liabilities Total Non-Current Liabilities
Market news
SV Wall Street
NSE: BIOCON.NS

Biocon Limited

CEO Mr. Siddharth Mittal BCom, CA, CPA
IPO Date April 7, 2004
Location India
Headquarters 20th KM, Hosur Road
Employees 16,315
Sector Healthcare
Industries
Pharmaceuticals Biotechnology
Description

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.

StockViz Staff

February 2, 2025

Any question? Send us an email